Evidentiary requirements and the medicines regulatory framework in Europe are integral parts of the access to medicines debate and deserve much more attention. Our session builds on last year’s agenda-setting session and will outline actionable recommendations for medicines regulatory reform in order to achieve meaningful public health needs-driven innovation for the benefit of all patients.

Furthermore, the conference comes at a critical juncture when Europe is debating the role of Health Technology Assessment (HTA), and how to ensure that public investment in medical R&D translates to the medicines we need being developed and made available at prices that patients and governments can afford. The session will draw the link between HTA and the regulatory environment and provide answers to the conundrum of weak evidence-high prices faced by policy-makers across Europe.

The session will be highly interactive and no presentations will be allowed in order to guarantee a lively and comprehensive conversation amongst panelists and with the audience.